CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes Clinical Trial

Official title:

A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03291444
• Other study ID #: 2017-XYNK-001
• Status: Recruiting
• Phase: Phase 1
• Start date: May 5, 2018
• Est. completion date: June 1, 2025

Study information

• Verified date: March 2024
• Source: Zhujiang Hospital
• Contact: Sanfang Tu, M.D, Ph.D
• Phone: 86-20-62782322
• Email: doctortutu[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Description:

A prospective study to evaluate the safety and efficacy of Chimeric antigen receptor T cells combined with Eps8 or WT1（Wilms tumor 1） peptide specific dendritic cell for patients with relapsed/refractory leukemia. There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and Myelodysplastic Syndrome. Progression free survival, overall Survival, overall response rate, and duration of response were monitored.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 1, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Tumor type: Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) according to the WHO criteria (at least 20% blasts in the marrow). All FAB subtypes except M3. Patients with Myelodysplastic Syndrome, category of Refractory Anemia with Excess Blasts (RAEB): RAEB I (WHO: medullary blast count = 10% and a peripheral blast count = 5%) and RAEB II (WHO: medullary blast count > 10% and/or > 5% peripheral blasts) can be included in the study in absence of other non-experimental treatment modalities.

2. Positive antigen for any of CD19, CD20, CD22, CD10, CD33, CD38, CD56, CD117, CD123, CD34, or Muc1.Simultaneously ,high expression of EPS8 or WT1 in acute leukemia.

3. Relapsed/Refractory leukemia patients:

• Did not achieve complete remission after 2 times of standard plan chemotherapy.

• Relapsed after first induction chemotherapy.

• Did not response to chemotherapy before HSCT or relapsed after HSCT.

• Cannot receive allo-HSCT or refuse to receive allo-HSCT.

• Relapsed after CAR-T cell infusion.

4. Age greater than 18 year and less than 80 years.

5. Objectively assessable parameters of life expectancy: more than 3 months.

6. Performance status: WHO PS grade 0-1 (ECOG performance status 0 or 1).

7. Meet the following criteria for apheresis:WBC >= 3,000/L, Hb >= 8.0 g/dL, platelet count >= 80,000/mm3, <= 600,000/mm3.

8. Pulmonary function: Peripheral blood oxygen saturation greater than 90%; Cardiac function: Left ventricular ejection fraction >60%.

9. Prior and concomitant associated diseases allowed with the exception of underlying autoimmune disease and positive serology for HIV/HBV/HCV.

10. No concomitant use of immunosuppressive drugs.

11. Adequate renal and liver function, i.e. creatinin, bilirubin, and aminotransferase =< 1.2 times the upper limit of normal.

12. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

13. Women of child-bearing potential should use adequate contraception prior to study entry and for the duration of study participation.

14. Written informed consent obtained.

Exclusion Criteria:

1. Patients with severe complications: cardiovascular disorders, respiratory disorders, renal dysfunction, immunodeficiency, hematological disorders, autoimmune diseases, sever allergy and severe infectious disease.

2. Patients who should receive systemic administration of steroid or immunosuppressive agents.

3. Presence of active brain metastases.

4. Pregnant, lactating, or possibly pregnant women, or willing to be pregnant.

5. Severe psychiatric disorder.

6. Active multiple cancers.

7. Patients have received other genetic therapy products.

8. Transfection efficiency was less than 30%.

9. Inappropriate for study entry judged by an attending physician.

10. patients who have sensitivity to drugs that provide local anesthesia.

Related Conditions & MeSH terms

• Acute Disease
• Leukemia
• Leukemia, Acute Lymphocytic (ALL)
• Leukemia, Acute Myelogenous (AML)
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia

Intervention

Biological:
• Chimeric antigen receptor T cells
After pretreatment, chimeric antigen receptor T cells will be transfused.
• peptide specific dendritic cell
After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.

Locations

Country	Name	City	State
China	Zhujiang Hospital, Southern Medical University	Guangzhou	Guangdong

Sponsors (3)

Lead Sponsor	Collaborator
Zhujiang Hospital	Shenzhen Geno-Immune Medical Institute, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of study related adverse events, according to NCI CTCAE Version 4.0	Incidence and severity of cytokine release syndrome(CRS): The systemic inflammatory response in patients with significantly increased IL-6 and other cytokines during the observation period is defined as CRS, which is divided into 1-5 grades, 1-2 Grade is mild, grade 3-5 is severe	up to 12 months
Secondary	Progression free survival time	Time from random to the first occurrence of disease progression.	2 years
Secondary	Overall survival time	Time from randomization to death due to any cause	2 years
Secondary	Overall response rate	The proportion of the total number of patients with complete remission and partial remission (CR+PR) after treatment in the total number of evaluable cases	2 years
Secondary	Duration of response	During the observation period, the time between complete remission of bone marrow (the ratio of bone marrow blast cells is less than 5%) to the recurrence of bone marrow (the ratio of bone marrow blast cells is greater than 5%) is the continuous remission time.	2 years